@article {Murphy154, author = {Conor C Murphy and Kathrin Greiner and Jarka Plskova and N Andrew Frost and John V Forrester and Andrew D Dick}, title = {Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis}, volume = {91}, number = {2}, pages = {154--156}, year = {2007}, doi = {10.1136/bjo.2006.105528}, publisher = {BMJ Publishing Group Ltd}, abstract = {Aim: To evaluate the responsiveness of the Vision core module 1 (VCM1) vision-related quality of life (VR-QOL) questionnaire to changes in visual acuity in patients with posterior and intermediate uveitis and to validate its use as a clinical end point in uveitis. Methods: Logarithm of the minimum angle of resolution visual acuity and VR-QOL using the VCM1 questionnaire were prospectively recorded in 37 patients with active posterior segment intraocular inflammation before starting systemic immunosuppression with ciclosporin, tacrolimus or the anti-tumour necrosis factor (TNF) agent, p55TNFr-Ig, and again 3 months later. Spearman analysis was used to correlate improvements in visual acuity and VR-QOL between baseline and 3 months. Results: The correlation between changes in visual acuity and VR-QOL was moderate to good for the worse eye (r = 0.47, p = 0.003), but poor for the better eye (r = -0.05, p = 0.91). The responsiveness indices effect size and standardised response mean were 0.57 and 0.59, respectively, showing that the VCM1 questionnaire is moderately responsive to immunsosuppressive therapy for active uveitis. Conclusion: Changes in VR-QOL measured with the VCM1 questionnaire correlated moderately well with changes in the worse eye visual acuity, suggesting that the VCM1 is a valid instrument for monitoring response to treatment in uveitis.}, issn = {0007-1161}, URL = {https://bjo.bmj.com/content/91/2/154}, eprint = {https://bjo.bmj.com/content/91/2/154.full.pdf}, journal = {British Journal of Ophthalmology} }